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Abstract Background: Current scientific evidence indicates that anemia in pregnancy,
regardless of severity, is associated with an increased risk of maternal and
fetal mortality. There is little published information about the bioavailability
and bioequivalence of formulations containing both iron and folic acid.
However, in vitro dissolution studies can provide important information on
the likely relative bioavailability of various formulations.
Aim: The objective of our study was to compare the in vitro dissolution of two
similar commercially available formulations of iron- and folic acid-containing
supplements, Folifer (Bialport – Produtos Farmaceˆuticos, S.A., Portugal) and
Ferroliver (SM Pharma c.a., Venezuela), in order to determine the in vitro
availability of their iron content. Folifer and Ferroliver were chosen because
they contained similar amounts of elemental iron.
Methods: The amount of iron released from each tablet was evaluated over a
4-hour period in three dissolution media replicating gastric or intestinal juices
with pH values ranging from 1.5 to 6.9. The samples were then titrated with a
solution of cerium ammonium sulfate in order to calculate the amount of iron
released in each specific pH condition. The percentage of dissolved iron was
calculated as a cumulative frequency, using the percentage of dissolved iron at
all timepoints. The dissolution similarity between the two commercially avail-
able formulations was evaluated using thee2 statistic formula.
Results: During a 4-hour dissolution test, Folifer released 59.4mg of iron
compared with 48.5mg released by Ferroliver. The value obtained for the
similarity factor, an indicator of likely bioequivalence, was 41.
Conclusion: These data suggest that Folifer releases more iron than
Ferroliver, and that the two formulations are not equivalent in vitro. The
superior dissolution of ferrous sulfate with Folifer compared with ferrous
fumarate in Ferroliver might be responsible for the observed difference.
Introduction
Iron deficiency is the most common and
widespread nutritional disorder in the world.[1-4]
It is estimated to account for 50% of anemia cases
and is considered one of the most important fac-
tors contributing to the burden of disease world-
wide.[5] The latest WHO survey, based on data
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gathered between 1993 and 2005, estimated the
worldwide prevalence of anemia in pregnant
women to be 41.8%.[5]
Recent evidence suggests that all grades of
anemia increase the risk of death.[6] Severe anemia
is associated with an increased risk ofmaternal and
childmortality.[5] Severe anemiamay directly cause
maternal death from heart failure, but moderate
anemia is also a factor that can influence a wom-
an’s ability to prevent and/or recover from com-
plications in pregnancy or post-partum, such as
hemorrhage and infection.[6]
The risk of folate deficiency is also increased
during pregnancy (mainly during periods of rapid
fetal growth) and lactation (when folate is lost in
breast milk).[7] In pregnancy, among other compli-
cations, the risk of neural tube defects[8] may be in-
creased up to 10-fold, depending on folate status.[7]
Furthermore, deficiencies of folate and iron
usually occur together, are particularly common
during pregnancy, lactation, and the post-partum
period, and are the two leading causes of nutri-
tional deficiency anemia.[9] However, it has been
reported that concomitant administration of iron
and folic acid facilitates a better physiological
response to the treatment of iron deficiency in
pregnancy than iron alone.[10]
Neither iron nor folic acid has been shown to
be pharmacologically active, but both play com-
plex roles in the normal metabolism of the body.
Both iron and folate are necessary for the normal
functioning of the hematopoietic system, as well
as many other essential metabolic processes.[7]
The WHO recommends universal supplementa-
tion for all pregnant women with iron 60mg/day
and folic acid 400 mg/day, from as early as possi-
ble in pregnancy.[11] However, despite this, ane-
mia continues to be one of the most common
causes of disease in pregnancy.[6,11]
Different combinations of iron- and folic acid-
containing supplements are commercially avail-
able, some of which contain similar amounts
of elemental iron. However, there are no pub-
lished studies comparing the bioavailability and
bioequivalence of these combinations containing
both iron and folic acid. Indeed, evaluating the
in vivo bioequivalence of such supplements can be
difficult to manage, because iron is both a phys-
iological constituent of the body and is present in
variable quantities in food. Similarly, the formu-
lation (e.g. a slow-release formulation) and solubility
of the particular iron salt can also influence the
bioavailability.[12-14] In these cases, in vitro dissolu-
tionmay be amore appropriate assessment method.
Furthermore, iron-containing drugs have un-
desirable side effects on the gastric mucosa;
therefore, it is common to design oral slow-release
formulations in order to improve tolerability and
adherence to treatment.[15] Under these conditions,
it might be appropriate to evaluate the release rate
of iron over time by performing a dissolution
test.[16] These tests evaluate the in vitro dissolution
rate (giving important information on the probable
bioavailability of the products) and allow assess-
ment of the degree of similarity between products
to indicate their in vitro bioequivalence.[17]
The aim of this studywas to compare the in vitro
dissolution of six tablets of two iron- and folic acid-
containing supplements, Folifer and Ferroliver.
Materials and Methods
Of the supplements commercially available for
iron-deficiency anemia prevention, two iron- and
folic acid-containing combinations were selected,
which contained different iron salts but similar
amounts of elemental iron. Folifer (Bialport –
Produtos Farmaceˆuticos, S.A., Portugal) is available
in film-coated tablet form, each tablet consisting
of a central core, containing approximately 90mg
of iron (as ferrous sulfate granules), and 1mg of
folic acid. For comparison purposes, Ferroliver
(SMPharma c.a., Venezuela)was used, another iron-
containing supplement in tablet form. Ferroliver
contains slightly more iron (99mg, as ferrous fu-
marate) compared with Folifer and a different
amount of folic acid (400mg), as well as containing
other compounds, including 0.0005mg of vitamin
B12 and 1mg of copper sulfate.
Reagents and Solutions
The following reagents and solutions were
used: concentrated hydrochloric acid 35–37%
(Sigma), iron sulfate (II) [Merck], concentrated
sulfuric acid 95–97% (Merck), sodium hydroxide
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(Sigma), monopotassium phosphate (Merck), am-
monium sulfate (Merck), cerium (Merck), potas-
sium iodide (Sigma), sodium thiosulfate (Merck),
soluble starch (Sigma), andmercuric iodide (Sigma).
The reagents and solutions were prepared as
follows:
Solution of ammonium sulfate and 0.1M cerium:
65g of ammonium sulfate and cerium was dis-
solved and mixed with 30mL of concentrated
sulfuric acid and 500mL of water. The mixture
was cooled and a further 1000mL of water was
added. Then, 25mL of ammonium sulfate and
cerium was added to 2 g of potassium iodide and
150mL of water. This was titrated immediately
with 0.1M sodium thiosulfate, using 1mL of
starch solution as an indicator.
Solution of ammonium sulfate and 0.01M cerium:
50mL of ammonium sulfate and 0.1M cerium was
diluted with 500mL water.
Starch solution: 1.0 g of soluble starch was
ground with 5mL of water and poured, stirring
constantly, into 100mL of boiling water, to which
10mg of mercuric iodide was added.
Gastric juice (pH 1.5): 90mL of concentrated
hydrochloric acid and 84mL of 10M sodium hy-
droxide were transferred to a 10L container. This
mixture was stirred, and approximately 9L of
water was added until the pH reached 1.50 – 0.05.
The solution was then made up to 10L with water.
Intestinal juice (pH 4.5): 8.7 g of mono-
potassium phosphate was added to a 10L con-
tainer.Water was added to the mixture, which was
stirred and diluted to 1L. 38mL of 10M sodium
hydroxide and 30mL of concentrated hydro-
chloric acid were then added. The solution was
stirred and adjusted until the pH was 4.50– 0.05.
The solution was thenmade up to 10L with water.
Intestinal juice (pH 6.9): The same procedure
was used as described in preparation of the in-
testinal juice pH 4.5, except the pH was adjusted
to 6.90 – 0.05.
Equipment
Weighing was carried out using a Mettler
Toledo XS205 balance. The dissolution tests were
carried out using the Vankel VK700 dissolution
testing station, while the titrimetric determination
of iron was evaluated using a Radiometer TIM800
automatic titrator.
In Vitro Dissolution Test
The amount of iron released from each tablet
was evaluated over a 4-hour period, using the
Vankel VK700 dissolution testing station and
one of three dissolution media replicating gastric
or intestinal juices with pH values ranging from
1.5 to 6.9. The test was performed by transferring
750mL of gastric juice (pH 1.5) to six dissolution
vessels and allowing the temperature to stabilize
at 37.0 – 0.5C. One tablet was placed in each
rotating basket within each vessel to begin the
dissolution test at 50 rpm. After 1 hour, a 200mL
sample was removed from each of the six dis-
solution vessels and accurately measured, and
20mL of sulfuric acid 1Mwas added. To quantify
the amount of iron released, this sample was then
titratedwith a solution of ceriumammonium sulfate
0.01M, using a platinum electrode as the indicator
electrode and mercury as a reference electrode.[18]
The remainder of the medium in the dis-
solution vessel was then discarded and replaced
with intestinal juice pH 4.5, which was allowed to
stabilize to 37.0 – 0.5C for 5minutes, and the test
proceeded for a further 1-hour rotation period to
allow further dissolution of the tablet. After 1 hour,
another 200mL sample was then taken from each
vessel and measured precisely, and 20mL of sul-
furic acid 1M was added. This was then titrated
with a solution of cerium ammonium sulfate 0.01M,
using a platinum electrode as the indicator electrode
andmercury as a reference electrode. The procedure
was then repeated using intestinal juice with a pH of
6.9 and a rotation period of 2 hours.
These conditions were established in order to
have aminimum of three timepoints, covering the
early, middle and late stages of the dissolution
profile, with the last timepoint corresponding to
the plateau of the dissolution profile.[19] More-
over, these three timepoints are sufficient to draw
a dissolution profile that can be used to compare
the different formulas.
The experimental method was validated as per
the International Conference on Harmonisation
(ICH) guideline Q2[20] and the United States
Bioequivalence of Iron-Containing Supplements 37
ª 2012 Patrı´cio et al., publisher and licensee Adis Data Information BV. Drugs R D 2012; 12 (1)
Pharmacopeia.[16] Linearity was assessed for the
three pHs by plotting three calibration plots, with
a correlation coefficient of 1.0000. Repeatability
and intermediate precision were assessed by an-
alyzing two sets of six tablets on different days,
with different analysts. The overall relative standard
deviation was less than 10% as per the validation
protocol for the three dissolution media, while
the absolute difference between mean dissolution
values for each pH was less than 10%. Accuracy
was evaluated for each pH by spiking placebo with
known amounts of iron (II). A mean recovery in-
dex within 100– 2% was obtained for the three
dissolution media. Robustness was evaluated by
changing the critical parameters of the method.
The results obtained were within 100– 5% of the
results obtained under standard conditions.
Statistical Methods
The percentage of dissolved iron for each tablet
at each timepoint was calculated as a cumulative
frequency, using the percentage of dissolved iron
at all timepoints that had been analyzed up to that
point. For each timepoint, the mean percentage of
dissolved iron was calculated from the six tablets,
together with the relative standard deviation. The
mean values were plotted in dissolution curves for
the two products under evaluation and allowed
comparison by means of the similarity factor, f2
(equation 1).












where n =number of points (two in this case);
R(t) =mean percentage of iron dissolved at time,
t, for Ferroliver; T(t) =mean percentage of iron
dissolved at time, t, for Folifer.
The similarity factor is a logarithmic recip-
rocal square root transformation of the sum of
squared errors and is a measurement of the sim-
ilarity in the percentage of dissolution between
the two curves. At least three mean dissolution
results from both curves obtained at the same
timepoints were used for the calculations. An f2
value of between 50 and 100 suggests that the two
dissolution profiles are similar.
Results
The results of the dissolution profiles and de-
gree of similarity for the two products are shown
in table I and figures 1 and 2.
During the first hour, 29.7mg and 32.7mg of
iron was released from Folifer and Ferroliver,
respectively. In percentage terms, the release rate
was similar, as the iron content of the two sup-
plements was similar. During the second hour,
Folifer showed a higher capacity for releasing
iron than Ferroliver, both in absolute terms
and in relative terms. After 4 hours, the amounts
of iron released by Folifer and Ferroliver were
59.4mg and 48.5mg, respectively.
The mean comparative dissolution profiles of
Folifer and Ferroliver were also assessed by
determining the similarity factor, f2, according to
the formula shown in equation 1. The f2 value
between the two formulations was 41, showing a
lack of similarity and in vitro bioequivalence.
Table I. Mean amount of iron released from two iron- and folic acid-containing supplements, Folifer and Ferroliver: results from an in vitro
dissolution study













1 hour (pH =1.5) 33 8.0 29.7 33 7.6 32.7
2 hours (pH = 4.5) 63 5.2 56.7 43 7.7 42.6
4 hours (pH = 6.9) 66 5.1 59.4 49 7.7 48.5
a Containing 90mg of iron as ferrous sulfate.
b Containing 99mg of iron as ferrous fumarate.
D =dissolution; Qt =amount of dissolved iron; RSD = relative standard deviation.
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Discussion
In vitro dissolution studies can provide important
information on bioavailability and bioequiva-
lence of various formulations. A dissolution test
can be used as a tool to identify formulation fac-
tors that influence, and may have a crucial effect
on, the bioavailability of a drug. Appropriate
in vitro dissolution testing may be used in place of
in vivo bioequivalence testing. Accordingly, dis-
solution testing should be investigated at differ-
ent pH values (normally pH 1.2, 4.5, and 6.8).
Results from our in vitro dissolution study
showed Folifer was superior to Ferroliver, re-
leasing 59.4mg versus 48.5mg of iron over a
4-hour period, respectively, indicating that Folifer
is likely to have increased bioavailability com-
pared with Ferroliver. This result is even more
surprising considering that Ferroliver has a
slightly higher elemental iron content.
In this respect, the role of the different iron
salts in each drug – ferrous sulfate (in Folifer)
and ferrous fumarate (in Ferroliver) – should be
noted. Ferrous sulfate has an improved dis-
solution profile compared with ferrous fumarate
because of its superior degree of solubility in
acid.[21] This difference is likely to be the main
reason for the observed results and the lack of
equivalence between the two products.
However, since the two products differ slightly
in their chemical composition, we cannot exclude
the possibility of bias in the study. While we rec-
ognize that this is a potential limitation of this stu-
dy, there is no known scientific rationale for folic
acid, vitamin B12, or copper sulfate significantly
influencing the in vitro dissolution of iron. The se-
lectivity of cerimetric titration for the quantitation
of iron (II) in the presence of inert excipients was
demonstrated in the validation results. Excipients
and other active ingredients found in the formulas
were not expected to have any relevant influence on
the assay, as they either did not have any relevant
oxidation-reduction behavior, or they were present
at very low levels relative to the amount of iron.
Finally, the information that arises from appli-
cation of the formula for calculating the similarity
factor (equation 1) shows both drugs have differ-
ent in vitro dissolution profiles and so are unlikely
to be bioequivalent.
This study reinforces the importance and dif-
ferentiation of ferrous sulfate and ferrous fuma-
rate as iron salts. Previous evidence suggests that
different iron salts show similar tolerability in
clinical use.[22] In two studies comparing the ab-
sorption of ferrous sulfate and ferrous fumarate
from fortified milk-based drinks, one study found
that ferrous sulfate was better absorbed than fer-
rous fumarate,[23] while absorption of ferrous
sulfate and ferrous fumarate did not differ sig-
nificantly in the second study.[24] Given the sig-
nificant effects that the type of salt may have on
in vitro dissolution, ferrous sulfate-containing
supplements such as Folifer may therefore be a





















Fig. 1. Dissolution profiles showing the mean percentage of iron


















Fig. 2. Dissolution profiles showing the mean absolute amount of
iron released over a 4-hour time period for Folifer and Ferroliver.
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in individuals at risk of iron/folate deficiencies,
such as pregnant and lactating women.
Conclusion
Despite containing similar amounts of ele-
mental iron, Folifer showed greater dissolution
of iron compared with Ferroliver. This study
highlights the importance of some iron salts (such
as ferrous sulfate) on the bioavailability of iron
supplements. Folifer and Ferroliver had dis-
similar dissolution profiles in vitro; differences in
the solubility of ferrous sulfate and ferrous fu-
marate may explain the lack of equivalence, and
this should be considered in clinical practice.
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